<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526782</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1904</org_study_id>
    <nct_id>NCT04526782</nct_id>
  </id_info>
  <brief_title>ENCOrafenib With Binimetinib in bRAF NSCLC</brief_title>
  <acronym>ENCO-BRAF</acronym>
  <official_title>A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor&#xD;
      Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Objective Response Rate at 6 months using RECIST1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration Response Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time from the date of the first documented response (CR or PR) to the earliest date of disease progression (RECIST 1.1), or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>about 24 months</time_frame>
    <description>Time from enrollment to first observation of progression (RECIST1.1) or date of death (from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>about 24 months</time_frame>
    <description>Time from enrollment until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, type and severity of adverse events</measure>
    <time_frame>From time of informed consent through treatment period and up to 30 days post last dose of study treatment (about 24 months)</time_frame>
    <description>Descriptive statistics of safety will be presented using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>BRAF V600E</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (1rst line)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (2nd line) - A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib: 450 mg (6 × 75 mg capsule) QD Binimetinib: 45 mg (3 × 15 mg tablet) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (2nd line) - B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel 75 mg/kg (D1=D22)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib 75 MG</intervention_name>
    <description>450 mg (6 × 75 mg capsule) per day</description>
    <arm_group_label>Cohort 1 (1rst line)</arm_group_label>
    <arm_group_label>Cohort 2 (2nd line) - A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binimetinib 15 MG</intervention_name>
    <description>45 mg (3 × 15 mg tablet) twice daily</description>
    <arm_group_label>Cohort 1 (1rst line)</arm_group_label>
    <arm_group_label>Cohort 2 (2nd line) - A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/kg (D1=D22)</description>
    <arm_group_label>Cohort 2 (2nd line) - B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have signed and dated an IRB/IEC approved written informed consent form&#xD;
             in accordance with regulatory and institutional guidelines. This must be obtained&#xD;
             before the performance of any protocol related procedures that are not part of normal&#xD;
             subject care.&#xD;
&#xD;
             Subjects must be willing and able to comply with scheduled visits, treatment schedule,&#xD;
             and laboratory testing.&#xD;
&#xD;
          2. Male or female aged at least 18 years old.&#xD;
&#xD;
          3. Histologically confirmed diagnosis of NSCLC that is currently Stage IV (M1a, M1b or&#xD;
             M1c AJCC 8th edition).&#xD;
&#xD;
          4. ECOG performance status of 0-1.&#xD;
&#xD;
          5. Able to swallow and retain oral medication.&#xD;
&#xD;
          6. Presence of a BRAFV600E mutation in lung cancer tissue as determined by a local&#xD;
             laboratory assay.&#xD;
&#xD;
          7. The Investigator must confirm prior to enrolment that the patient has adequate tumor&#xD;
             tissue available to determine BRAFV600E mutation status by central laboratory for&#xD;
             confirmation.&#xD;
&#xD;
             Note: Tumor tissue collected after the patient was diagnosed with metastatic disease&#xD;
             is preferred.&#xD;
&#xD;
             Tumor tissue sample must not be from locations previously radiated. Tumor sample must&#xD;
             be 1 block or 8 to 15 unstained slides of analyzable tissue.&#xD;
&#xD;
          8. Patients i) (COHORT A) who are either treatment-naïve (e.g., no prior systemic therapy&#xD;
             for advanced/metastatic disease), ii) (COHORT B) who have received 1) first-line&#xD;
             platinum-based chemotherapy OR 2) first-line treatment with an anti-PD-1/L-1 inhibitor&#xD;
             given alone or in combination with platinum-based chemotherapy or in combination with&#xD;
             immunotherapy (e.g, ipilimumab) with or without platinum-based chemotherapy.&#xD;
&#xD;
             Note: Alternative chemotherapy regimens are acceptable if the patient was platinum&#xD;
             intolerant or ineligible.&#xD;
&#xD;
             Patients with early stage disease (e.g., Stages I-III) who have had surgery followed&#xD;
             by chemotherapy (e.g., treatment in the adjuvant setting), and present with new&#xD;
             lesions or evidence of disease recurrence (e.g., metastatic disease), within 12 months&#xD;
             of completing chemotherapy, would be considered as had received a first-line therapy.&#xD;
&#xD;
             Maintenance therapy given after first-line therapy in the metastatic setting will not&#xD;
             be considered a separate regimen, provided there was no documentation of disease&#xD;
             progression between completion of first-line therapy and the start of maintenance&#xD;
             therapy.&#xD;
&#xD;
          9. Presence of measurable disease based on RECIST v1.1.&#xD;
&#xD;
         10. Adequate bone marrow function characterized by the following at screening:&#xD;
&#xD;
             i) ANC ≥ 1.5 × 109/L; ii) Platelets ≥ 100 × 109/L; iii) Hemoglobin ≥ 8.5 g/dL (with or&#xD;
             without blood transfusions).&#xD;
&#xD;
         11. Adequate hepatic and renal function characterized by the following at screening:&#xD;
&#xD;
             i) Total bilirubin ≤ 1.5 × ULN and &lt; 2 mg/dL; OR total bilirubin &gt;1.5 × ULN with&#xD;
             indirect bilirubin &lt; 1.5 × ULN; ii) ALT and AST ≤ 2.5 × ULN, or ≤ 5 × ULN in presence&#xD;
             of liver metastases; iii) Serum creatinine ≤ 1.5 × ULN; or calculated creatinine&#xD;
             clearance ≥ 50 mL/min by Cockcroft-Gault formula; or estimated glomerular filtration&#xD;
             rate&gt;50 mL/min/1.73m2.&#xD;
&#xD;
         12. Female patients of childbearing potential as described in Appendix 1, must have a&#xD;
             negative serum β HCG test result.&#xD;
&#xD;
         13. Female patients of childbearing potential must agree to use methods of contraception&#xD;
             that are highly effective or acceptable, as described in Appendix 1, and to not donate&#xD;
             ova from Screening until 30 days after the last dose of study treatment.&#xD;
&#xD;
         14. Male patients must agree to use methods of contraception that are highly effective or&#xD;
             acceptable, as described in Appendix 1, and to not donate sperm from Screening until&#xD;
             90 days after the last dose of encorafenib and binimetinib or until 6 months after the&#xD;
             last dose of docetaxel.&#xD;
&#xD;
         15. Patient covered by a national health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with nonsquamous carcinoma who have documentation of any of the following:&#xD;
             EGFR mutation, ALK fusion oncogene or ROS1 rearrangement.&#xD;
&#xD;
          2. Previous treatment with any other BRAF inhibitor (e.g., dabrafenib, vemurafenib…), or&#xD;
             any other MEK inhibitor (e.g., trametinib, cobimetinib…) prior to screening and&#xD;
             enrolment.&#xD;
&#xD;
          3. Previous treatment with docetaxel for Cohort B&#xD;
&#xD;
          4. Patients who have received more than 1 prior line of systemic therapy in the&#xD;
             advanced/metastatic setting for Cohort B.&#xD;
&#xD;
             Note: Generally, treatments that are separated by an event of progression are&#xD;
             considered to represent another line of therapy.&#xD;
&#xD;
             Any therapeutic intervention including systemic therapy, surgery concurrent with or&#xD;
             followed by systemic therapy, radiation concurrent with systemic therapy, or&#xD;
             stereotactic radiation/radiosurgery, initiated or added to an existing therapy for&#xD;
             oligometastatic disease will be considered a new line of therapy.&#xD;
&#xD;
             Palliative radiation to solitary lesions is permitted and will not be considered a new&#xD;
             line of therapy.&#xD;
&#xD;
             Surgery/radiosurgery for CNS metastases is permitted and will not be considered a line&#xD;
             of therapy as long as the surgery/radiosurgery was not given with systemic therapy&#xD;
             (neoadjuvant or adjuvant).&#xD;
&#xD;
             Surgery followed by chemotherapy in the metastatic setting will be considered a line&#xD;
             of therapy.&#xD;
&#xD;
          5. Receipt of anticancer therapies or investigational drugs within the following&#xD;
             intervals before the first administration of study treatment:&#xD;
&#xD;
             i) ≤14 days for chemotherapy, targeted small molecule therapy, radiation therapy,&#xD;
             immunotherapy, or antineoplastic biologic therapy (e.g., erlotinib, crizotinib,&#xD;
             bevacizumab etc.).&#xD;
&#xD;
             ii) ≤14 days or 5 half-lives (minimum of 14 days) for investigational agents or&#xD;
             devices. For investigational agents with long half-lives (e.g., &gt; 5 days), enrolment&#xD;
             before the fifth half-life requires sponsor approval.&#xD;
&#xD;
             iii) Palliative radiation therapy must be complete 7 days prior to the first dose of&#xD;
             study treatment.&#xD;
&#xD;
          6. Patients who have had major surgery (e.g., inpatient procedure with regional or&#xD;
             general anesthesia) ≤ 6 weeks prior to start of study treatment.&#xD;
&#xD;
          7. For cohort B : Patient has not recovered to ≤Grade 1 from toxic effects of prior&#xD;
             therapy and/or complications from prior surgical intervention before starting study&#xD;
             treatment.&#xD;
&#xD;
             Note: Stable chronic conditions (≤ Grade 2) that are not expected to resolve (e.g.,&#xD;
             neuropathy, myalgia, alopecia, and prior therapy-related endocrinopathies) are&#xD;
             exceptions.&#xD;
&#xD;
          8. Current use of a prohibited medication (including herbal medications, supplements, or&#xD;
             foods), or use of a prohibited medication ≤1 week prior to the start of study&#xD;
             treatment.&#xD;
&#xD;
          9. Impairment of gastrointestinal function or disease which may significantly alter the&#xD;
             absorption of oral study treatment (e.g., uncontrolled nausea, vomiting or diarrhea,&#xD;
             malabsorption syndrome, small bowel resection).&#xD;
&#xD;
         10. Impaired cardiovascular function or clinically significant cardiovascular diseases,&#xD;
             including any of the following:&#xD;
&#xD;
             i) History of acute myocardial infarction, acute coronary syndromes (including&#xD;
             unstable angina, coronary artery bypass graft, coronary angioplasty or stenting) ≤ 6&#xD;
             months prior to start of study treatment; ii) Congestive heart failure requiring&#xD;
             treatment (New York Heart Association Grade ≥2); iii) LVEF &lt; 50% as determined by MUGA&#xD;
             or ECHO; iv) Uncontrolled hypertension defined as persistent systolic blood pressure&#xD;
             ≥150 mmHg or diastolic blood pressure ≥100 mmHg despite optimal therapy; v) History or&#xD;
             presence of clinically significant cardiac arrhythmias (including uncontrolled atrial&#xD;
             fibrillation or uncontrolled paroxysmal supraventricular tachycardia); vi) Baseline&#xD;
             QTcF interval ≥480 ms or a history of prolonged QT syndrome.&#xD;
&#xD;
         11. History of thromboembolic or cerebrovascular events ≤12 weeks prior to the first dose&#xD;
             of study treatment. Examples include transient ischemic attacks, cerebrovascular&#xD;
             accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein&#xD;
             thrombosis or pulmonary emboli. Note: Patients with either deep vein thrombosis or&#xD;
             pulmonary emboli that does not result in hemodynamic instability are allowed to enrol&#xD;
             as long as they are on a stable dose of anticoagulants for at least 4 weeks. Note:&#xD;
             Patients with thromboembolic events related to indwelling catheters or other&#xD;
             procedures may be enrolled.&#xD;
&#xD;
         12. History or current evidence of RVO (Retinal Vein Occlusion) or current risk factors&#xD;
             for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyper&#xD;
             viscosity or hypercoagulability syndromes); history of retinal degenerative disease.&#xD;
&#xD;
         13. Concurrent neuromuscular disorder that is associated with the potential of elevated CK&#xD;
             (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis,&#xD;
             spinal muscular atrophy).&#xD;
&#xD;
         14. Evidence of active, noninfectious pneumonitis, history of interstitial lung disease&#xD;
             that required oral or intravenous glucocorticoid steroids for management.&#xD;
&#xD;
         15. Evidence of HBV or HCV infection. Note: Patients with laboratory evidence of cleared&#xD;
             HBV or HCV infection may be enrolled. Note: Patients with no prior history of HBV&#xD;
             infection who have been vaccinated against HBV and who have a positive antibody&#xD;
             against hepatitis B surface antigen as the only evidence of prior exposure may enrol.&#xD;
&#xD;
         16. Patient who aas has a known history of a positive test for HIV or known AIDS.&#xD;
&#xD;
         17. Active infection requiring systemic therapy.&#xD;
&#xD;
         18. Patients with symptomatic brain metastasis, leptomeningeal disease or other active CNS&#xD;
             metastases are not eligible.&#xD;
&#xD;
             Note: Patients with previously treated or not treated brain metastases may participate&#xD;
             provided they are stable (e.g., without evidence of progression by radiographic&#xD;
             imaging for at least 28 days before the first dose of study treatment and neurologic&#xD;
             symptoms have returned to baseline) Patients must have no evidence of new or enlarging&#xD;
             brain metastases or CNS edema.&#xD;
&#xD;
             Patient must have discontinued use of steroids at least 7 days before the first dose&#xD;
             of study treatment.&#xD;
&#xD;
         19. Concurrent or previous other malignancy within 2 years of study entry, except&#xD;
             curatively treated basal or squamous cell skin cancer, prostate intraepithelial&#xD;
             neoplasm, carcinoma in-situ of the cervix, Bowen's disease and Gleason 6 prostate&#xD;
             cancer.&#xD;
&#xD;
         20. Known sensitivity or contraindication to any component of study treatment or their&#xD;
             excipients.&#xD;
&#xD;
         21. Pregnancy confirmed by a positive β-HCG laboratory test result, or breastfeeding&#xD;
             (lactating).&#xD;
&#xD;
         22. Other severe, acute or chronic medical or psychiatric condition(s) or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or study&#xD;
             treatment administration or that may interfere with the interpretation of study&#xD;
             results and, in the judgment of the Investigator, would make the patient an&#xD;
             inappropriate candidate for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Planchard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy (Villejuif - France)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Ricordel</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes,France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elodie Amour</last_name>
    <phone>+33156811045</phone>
    <email>contact@ifct.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Annemasse - CH</name>
      <address>
        <city>Ambilly</city>
        <zip>74100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROMAND, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Bigot, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers - CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Hureaux, Dr</last_name>
    </contact>
    <investigator>
      <last_name>José Hureaux, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé d'Antony</name>
      <address>
        <city>Antony</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislas ROPERT</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avignon - Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alma STANCU, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie COUSIN, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boulogne - Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brest - CHU</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaux GEIER, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannick MADELAINE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel MOREAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Bernard AULIAC, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie LAGRANGE</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis MORO-SIBILOT</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Roche Sur Yon - CH</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyril GUIBERT, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MOLINIER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis CORTOT, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Egenod, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurice Pérol, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Madroszyk, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale TOMASINI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier - CHRU</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit ROCH, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mulhouse - GHRMSA</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nancy - Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle CLEMENT-DUCHENE, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Wislez, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Fallet, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard Zalcman, PhD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clémence BASSE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Général - Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Renault, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon - URCOT</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien COURAUD, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Ricordel, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian GUISIER</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Quentin - CH</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Dayen, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric BIGOT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline Mascaux, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Pneumologie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Mazieres, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tours - CHU</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine CARMIER, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Villefranche-Sur-Saône - Hôpital Nord-Ouest</name>
      <address>
        <city>Villefranche-Sur-Saône</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc ODIER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Planchard, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ifct.fr/index.php/fr/la-recherche/item/2212-ifct-1904-encobraf</url>
    <description>IFCT website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>encorafenib</keyword>
  <keyword>binimetinib</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

